RWRuirui Wang

Ruirui Wang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ruirui Wang has a total of 63 co-authors. Here are the top co-authors by number of shared publications:

  • Yonghong Zhang

    Medical College of Soochow University

    9 shared publications
  • Mengyao Shi

    Department of Epidemiology, School of Public Health, Jiangsu Key Laboratory of Preventive and Translational Medicine for Major Chronic Non‐Communicable Diseases, MOE Key Laboratory of Geriatric Diseases and Immunology Suzhou Medical College of Soochow University Suzhou Jiangsu China

    6 shared publications
  • Pinni Yang

    Department of Epidemiology, School of Public Health, Jiangsu Key Laboratory of Preventive and Translational Medicine for Major Chronic Non‐Communicable Diseases, MOE Key Laboratory of Geriatric Diseases and Immunology Suzhou Medical College of Soochow University Suzhou Jiangsu China

    6 shared publications
  • Tan Xu

    Department of Epidemiology, School of Public Health and Jiangsu Key Laboratory of Preventive and Translational Medicine for Geriatric Diseases, Suzhou Medical College of Soochow University, Suzhou, China

    5 shared publications
  • Aili Wang

    Department of Epidemiology, School of Public Health and Jiangsu Key Laboratory of Preventive and Translational Medicine for Geriatric Diseases, Suzhou Medical College of Soochow University, Suzhou, Jiangsu, China

    4 shared publications
  • Yanbo Peng

    Department of Neurology, Affiliated Hospital of North China University of Science and Technology, Tangshan, Hebei, China

    4 shared publications

Latest Publications

  • Associations of the Baseline Level and Change in Estimated Glucose Disposal Rate With Incident Dementia, Cognitive Functions, and Brain Structure: Findings From the UK Biobank Study

    by Wenyang Han, Yiqun Li, Pinni Yang, Yiming Jia, Lulu Sun, Ruirui Wang, Mengyao Shi, Xiaowei Zheng, Yonghong Zhang, Zhengbao Zhu

    Aims: The aim of this study was to investigate the association of baseline and changes of estimated glucose disposal rate (eGDR) with incident dementia, cognitive functions, and brain structure based on the UK Biobank. Methods: A total of 440 295 participants, and 12 723 (with two measurements of eGDR) without dementia at baseline (followed until November 2022.) were analyzed. Results: Higher baseline eGDR level was associated with decreased risk of incident dementia (HR = 0.43, 95% CI: 0.39–0.47). Compared to persistently low level of eGDR (Class 1), those with high level decreasing (Class 3, HR = 0.60, 95% CI: 0.35–0.95) and persistently high level (Class 4, HR = 0.47, 95% CI: 0.28–0.77) of eGDR were associated with decreased risks of dementia. In addition, those with higher baseline and persistently high level of eGDR were associated with favorable cognitive functions, and better brain structure. Conclusion: A high baseline eGDR level, high level decreasing, and persistently high level in eGDR level are associated with decreased risks of incident dementia.

  • Open Access

    Associations of the Baseline Level and Change in Triglyceride Glucose‐Body Roundness Index With Cardiovascular Diseases: Two Large Prospective Cohorts in Europe and Asia

    by Wen‐Yang Han, Yi‐Qun Li, Pin‐Ni Yang, Yi‐Ming Jia, Lu‐Lu Sun, Rui‐Rui Wang, Meng‐Yao Shi, Xiao‐Wei Zheng, Yong‐Hong Zhang, Zheng‐Bao Zhu

    The aim of this study was to investigate the association of baseline and changes of TyG‐BRI with incident CVD based on the UK Biobank and China Health and Retirement Longitudinal Study (CHARLS). A total of 418,510 and 7923 individuals from the UK Biobank and CHARLS were included in Analysis 1 (baseline TyG‐BRI with CVD risk). In Analysis 2 (change in TyG‐BRI with CVD risk), a total of 11,682 and 4637 participants were included in Cox proportional hazard models. We found participants with the highest baseline TyG‐BRI level were associated with increased risk of incident CVD in UK Biobank (HR = 1.45, 95% CI: 1.39–1.52) and CHARLS (HR = 1.35, 95% CI: 1.13–1.61). Multivariable‐adjusted restricted cubic spline analyses presented positive linear associations between TyG‐BRI and CVD risk. Compared to persistently low levels of TyG‐BRI (Class 1), those with persistently high levels (Class 3: 1.23 (1.02–1.49) and 1.42 (1.11–1.55); Class 4: 1.48 (1.17–1.87) and 1.45 (1.16–2.28); Class 5: 2.58 (1.86–3.58) and 1.63 (1.16–2.28) for UK Biobank and CHARLS) in follow‐up were associated with increased risks of incident CVD. In conclusion, a high baseline TyG‐BRI level and different changes in TyG‐BRI level are associated with increased risks of incident CVD.

  • Estimated Glucose Disposal Rate and Risk of Vascular Events and Death in Type 2 Diabetes in the ADVANCE Study

    by Ruirui Wang, Yonghong Zhang, Yijie Gao, Linan Chen, Xiaoying Chen, Ruth Peters, Craig S. Anderson, Michel Marre, Stephen Harrap, Pavel Hamet, et al.

    Aims: To determine the association of insulin resistance, assessed using the estimated glucose disposal rate (eGDR), and the risk of adverse clinical outcomes, and determine any effect modification on the efficacy of glucose‐ and blood pressure (BP)‐lowering treatments. Materials and Methods: Briefly, 11 140 participants with type 2 diabetes (T2D) were recruited from 20 countries for the Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation (ADVANCE) trial. eGDR was derived from waist circumference, hypertension status and glycated haemoglobin, calculated in 11 081 participants. Multivariable Cox models were used to estimate hazard ratios (HRs) of the association of eGDR with clinical events. Results: Over a median of 5 years of follow‐up, 2117 participants (19.1%) experienced a major macrovascular or microvascular event. Compared with individuals in the lowest quarter of eGDR, those in the highest quarter had significantly lower risks of a composite major macrovascular and microvascular event (HR 0.72, 95% CI 0.62–0.84). Similar associations were seen for major macrovascular events (HR 0.68, 95% CI 0.55–0.85), major microvascular events (HR 0.78, 95% CI 0.63–0.96), all‐cause mortality (HR 0.69, 95% CI 0.55–0.86), and cardiovascular mortality (HR 0.62, 95% CI 0.45–0.85). No significant effect modification was observed across eGDR quarters for the efficacy or safety of intensive glucose control (vs. standard control) or BP–lowering treatment (vs. placebo). Conclusion: These findings highlight the value of eGDR as a prognostic marker for T2D. Intensive glucose‐ and BP‐lowering treatments remain beneficial regardless of insulin resistance status. Trial Registration: ClinicalTrials.gov identifier: NCT00145925


  • Open Access

    Cumulative blood pressure and risk of dementia and cognitive decline: a systematic review and meta-analysis

    by Ruirui Wang, Yijie Gao, Nicole Ee, Fope Akinyede, Xiaoyue Xu, Linan Chen, Shangzhi Xiong, Xiaoying Chen, Craig S. Anderson, Katie Harris, et al.


  • Plasma bone morphogenetic proteins 9 and major cardiovascular events and mortality after acute ischemic stroke: a prospective multicenter study

    by Ruirui Wang, Yi Chen, Xiangyan Yin, Xiaoxiao Wang, Xuefen Zheng, Xinyu Yang, Jinhuan Zhou, Tan Xu, Yonghong Zhang

  • Open Access

    The association of early life factors with depression and anxiety in adults aged 40–69 years: a population-based cohort study

    by Ruirui Wang, Mengyao Shi, Qilu Zhang, Jing Zhang, Lulu Sun, Yiming Jia, Zhengbao Zhu, Tan Xu, Yonghong Zhang

    This study was aimed to explore the longitudinal association of five early life factors (breastfeeding, maternal smoking around birth, birth weight, being born in a multiple birth, and adoption) during the in-utero, perinatal, and early childhood development stages with incidence of depression and anxiety in adults aged 40–69 years. We used data from the UK biobank, 5,02,394 participants aged 40–69 years were recruited between 2006 and 2010. Participants provided information on early life exposures through touchscreen questionnaires or verbal interviews at baseline. The primary outcomes, depression, and anxiety, were defined according to the International Classification of Diseases, 10th Revision. Hazard ratios (HR) and 95% confidence intervals (CI) for each factor were reported. During a median follow-up of 13.6 years, 16,502 (3.55%) participants developed depression, and 15,507 (3.33%) developed anxiety. After adjusting for potential confounders, increased risk of depression was found to be significantly associated with non-breastfeeding (HR, 1.08; 95% CI, 1.04–1.13), maternal smoking around birth (HR, 1.19; 95% CI, 1.14–1.23), being born in multiple births (HR, 1.16; 95% CI, 1.05–1.27), low birth weight (HR, 1.14; 95% CI, 1.07–1.22), and being an adoptee (HR, 1.42; 95% CI, 1.28–1.58). Increased risk of anxiety was associated with non-breastfeeding (HR, 1.09; 95% CI, 1.04–1.13), maternal smoking around birth (HR, 1.11; 95% CI, 1.07–1.16), being born in a multiple births (HR, 1.05; 95% CI, 0.95–1.17), low birth weight (HR, 1.12; 95% CI, 1.05–1.20), and being an adoptee (HR, 1.25; 95% CI, 1.10–1.41). Each of these five early life factors can be considered as early life risk factors for incident depression and anxiety in adulthood independently. The dose-response relationship was also observed, suggesting that with an increase in the number of early life risk factors, the likelihood of experiencing depression and anxiety also increased. These findings highlighted the imperative consideration of early life factors in comprehending the susceptibility to mental health disorders later in life, including non-breastfeeding, maternal smoking around birth, being born in multiple births, low birth weight, and being an adoptee.


  • Twenty-four-hour blood pressure trajectories and clinical outcomes in patients who had an acute ischaemic stroke

    by Ruirui Wang, Yang Liu, Qilu Zhang, Jing Zhang, Hao Peng, Mengyao Shi, Yanbo Peng, Tian Xu, Aili Wang, Tan Xu, et al.

    Objective The management of blood pressure (BP) in acute ischaemic stroke remains a subject of controversy. This investigation aimed to explore the relationship between 24-hour BP patterns following ischaemic stroke and clinical outcomes. Methods A cohort of 4069 patients who had an acute ischaemic stroke from 26 hospitals was examined. Five systolic BP trajectories were identified by using latent mixture modelling: trajectory category 5 (190–170 mm Hg), trajectory category 4 (180–140 mm Hg), trajectory category 3 (170–160 mm Hg), trajectory category 2 (155–145 mm Hg) and trajectory category 1 (150–130 mm Hg). The primary outcome was a composite outcome of death and major disability at 3 months poststroke. Results Patients with trajectory category 5 exhibited the highest risk, while those with trajectory category 1 had the lowest risk of adverse outcomes at 3-month follow-up. Compared with the patients in the trajectory category 5, adjusted ORs (95% CIs) for the primary outcome were 0.79 (0.58 to 1.10), 0.70 (0.53 to 0.93), 0.64 (0.47 to 0.86) and 0.47 (0.33 to 0.66) among patients in trajectory category 4, trajectory category 3, trajectory category 2 and trajectory category 1, respectively. Similar trends were observed for death, vascular events and the composite outcome of death and vascular events. Conclusion Patients with persistently high BP at 180 mm Hg within 24 hours of ischaemic stroke onset had the highest risk, while those maintaining stable BP at a moderate-low level (150 mm Hg) or even a low level (137 mm Hg) had more favourable outcomes.


  • Open Access

    Causal Effects of YKL‐40 on Ischemic Stroke and Its Subtypes: A 2‐Sample Mendelian Randomization Study

    by Qingyun Xu, Lulu Sun, Yinan Wang, Ruirui Wang, Yiming Jia, Daoxia Guo, Mengyao Shi, Pinni Yang, Yonghong Zhang, Zhengbao Zhu

    Background: Chitinase‐3 like protein 1 (CHI3L1, YKL‐40) was reported to be implicated in the development of ischemic stroke, but whether the association between them was causal remained unclear. We conducted a 2‐sample Mendelian randomization study to explore the associations of genetically determined plasma YKL‐40 with ischemic stroke and its subtypes (large artery stroke, small vessel stroke, and cardioembolic stroke). Methods and Results: Based on genome‐wide association study data of 3394 European‐descent individuals, we selected 13 single‐nucleotide polymorphisms associated with plasma YKL‐40 as genetic instruments. Summary data about ischemic stroke and its subtypes were obtained from the Multiancestry Genome‐wide Association Study of Stroke Consortium, involving 34 217 ischemic stroke cases and 406 111 controls of European ancestry. We used the inverse‐variance weighted method followed by a series of sensitivity analyses to assess the causal associations of plasma YKL‐40 with ischemic stroke and its subtypes. The primary analysis showed that genetically determined high YKL‐40 levels were associated with increased risks of large artery stroke (odds ratio [OR], 1.08 [95% CI, 1.04–1.12]; P =1.73×10 −4 ) and small vessel stroke (OR, 1.05 [95% CI, 1.01–1.09]; P =7.96×10 −3 ) but not with ischemic stroke or cardioembolic stroke. Sensitivity analyses further confirmed these associations, and Mendelian randomization‐Egger indicated no evidence of genetic pleiotropy. In addition, supplementary analysis based on the summary data from the Olink proximity extension assay cardiovascular I (Olink CVD‐I) panel showed that high YKL‐40 levels were positively associated with the risks of large artery stroke (OR, 1.15 [95% CI, 1.08–1.22]; P =4.16×10 −6 ) but not with small vessel stroke. Conclusions: Genetically determined high plasma YKL‐40 levels were causal associated with increased risks of large artery stroke.


  • Open Access

    HS‐CRP Modifies the Prognostic Value of Platelet Count for Clinical Outcomes After Ischemic Stroke

    by Fanghua Liu, Pinni Yang, Yinan Wang, Mengyao Shi, Ruirui Wang, Qingyun Xu, Yanbo Peng, Jing Chen, Jintao Zhang, Aili Wang, et al.

    Background: We examined whether the relationship between baseline platelet count and clinical outcomes is modulated by HS‐CRP (high‐sensitivity C‐reactive protein) in patients with ischemic stroke. Methods and Results: A total of 3267 patients with ischemic stroke were included in the analysis. The primary outcome was a combination of death and major disability at 1 year after ischemic stroke. Secondary outcomes included major disability, death, vascular events, composite outcome of vascular events or death, and an ordered 7‐level categorical score of the modified Rankin Scale at 1 year. Multivariate logistic regression and Cox proportional hazards regression models were used to assess the association between the baseline platelet count and clinical outcomes stratified by HS‐CRP levels when appropriate. There was an interaction effect of platelet count and HS‐CRP on the adverse clinical outcomes after ischemic stroke (all P interaction P trend <0.05). Conclusions: The HS‐CRP levels had a modifying effect on the association between platelet count and clinical outcomes in patients with ischemic stroke. Elevated platelet count was significantly associated with adverse clinical outcomes in patients with ischemic stroke with high HS‐CRP levels, but not in those with low HS‐CRP levels. These findings suggest that strategies for anti‐inflammatory and antiplatelet therapy should be developed according to the results of both platelet and HS‐CRP testing.


  • Open Access

    High-sensitivity C-reactive protein modifies the prognostic value of platelet count for clinical outcomes after ischemic stroke

    by Fanghua Liu, Pinni Yang, Yinan Wang, Mengyao Shi, Ruirui Wang, Qingyun Xu, Yanbo Peng, Jing Chen, Jintao Zhang, Aili Wang, et al.

    Background: Platelets play a critical role in the formation of thrombosis and embolism, and high-sensitivity C-reactive protein (HS-CRP) is an important indicator of inflammation, which contribute to the development of ischemic stroke development. This study aimed to examine whether the relationship between baseline platelet count and adverse clinical outcomes is modulated by HS-CRP in patients with ischemic stroke. Methods: A total of 3267 patients with ischemic stroke were included in the analysis. The primary outcome was a combination of death and major disability (modified Rankin Scale [mRS] score ≥3) at 1 year after ischemic stroke. Secondary outcomes included major disability, death, vascular events, composite outcome of vascular events or death, and an ordered 7-level categorical score of the mRS at 1 year. Multivariate logistic regression and Cox proportional hazards regression models were used to assess the association between the baseline platelet count and clinical outcomes stratified by HS-CRP levels when appropriate, odds ratio (OR) or hazard ratio (HR) and 95% confidence interval (CI) were calculated for the highest quartiles of platelet counts compared with the lowest quartile. Results: The elevated platelet count was associated with the primary outcome (OR, 3.14;95% CI, 1.77-5.58), major disability (OR, 2.07;95%CI, 1.15-3.71), death (HR, 2.75;95%CI, 1.31-5.79), composite outcome of vascular events or death (HR, 2.57;95%CI, 1.38-4.87), and the ordered 7-level categorical score of the mRS at 1 year (OR, 2.01 [95%CI, 1.33-3.04]) among patients with high HS-CRP levels (all P trend 0.05) in those with low HS-CRP levels. There was an interaction effect of platelet count and HS-CRP on the primary outcome, death, composite outcome of vascular events or death, and the ordered 7-level categorical score of the mRS at 1 year after ischemic stroke (all P interaction <0.05). Conclusions: An elevated platelet count was associated with adverse clinical outcomes in ischemic stroke patients with high HS-CRP levels but not in those with low HS-CRP levels, the HS-CRP level had a modifying effect on the association between platelet count and clinical outcomes in patients with ischemic stroke, suggesting that strategies for anti-inflammatory and antiplatelet therapy should be developed according to the results of both platelet and HS-CRP testing.